Down 74% Over the Past Year, Is Moderna Stock a Buy?

Moderna (NASDAQ: MRNA) faces a steep revenue decline, with sales plummeting from over $19 billion in 2022 to $3.24 billion in 2024 and projected even lower for 2025, causing its stock to fall 74% year-over-year. The company's future hinges on its pipeline, primarily its Phase 3 oncology programs for melanoma and lung cancer, and respiratory vaccines, as it pivots from its COVID-19 vaccine dependency. Despite a recent pediatric COVID vaccine approval, the long-term investment thesis is speculative and requires significant patience, banking on the successful development and approval of its oncology assets targeting a projected $900 billion market by 2034.

Analysis

Moderna's financial profile has undergone a dramatic contraction, with revenue plummeting from over $19 billion in 2022 to an estimated $3.24 billion in 2024, and a further decline to between $1.5 billion and $2.5 billion guided for 2025. This revenue collapse, driven by shrinking COVID-19 vaccine demand, has resulted in a 74% year-over-year stock decline and a shift to unprofitability, rendering traditional earnings-based valuation metrics unusable in the near term. Consequently, the investment thesis for Moderna is now entirely forward-looking and speculative, centered on the success of its clinical pipeline. The most significant potential valuation catalysts are its late-stage oncology programs, which apply mRNA technology to melanoma and non-small cell lung cancer, targeting a market projected to reach $900 billion by 2034. Additionally, Phase 3 trials for a seasonal flu vaccine and a flu/COVID combination shot represent nearer-term opportunities, though the oncology segment holds the key to substantial long-term growth. The stock's current valuation at 3.6 times fiscal 2024 sales reflects a company in transition, where investors must weigh the severe near-term fundamental weakness against the high-risk, high-reward potential of future drug approvals.

Key Decisions for Investors

• Investors should treat Moderna as a long-term, high-risk holding suitable only for portfolios with a high tolerance for volatility, as any upside is contingent on future clinical trial success rather than current financial performance.
• Closely monitor clinical trial catalysts, specifically data readouts from the Phase 3 programs in oncology (melanoma, lung cancer) and respiratory vaccines, as these events will be the primary drivers of the stock's performance.
• Given the weak revenue outlook for 2025, consider that further share price deterioration is possible, which could present more attractive entry points for investors who are bullish on the long-term pipeline but cautious about near-term headwinds.
• The investment case hinges on conviction in the company's mRNA platform; investors who believe in its application beyond COVID-19 may consider accumulating a position, while those skeptical of clinical success should avoid the stock due to the lack of fundamental support.